About MiMedx Group
MiMedx Group is a publicly listed company based in Marietta (United States) founded in 1985. Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics. The company has 837 employees. MiMedx Group has completed 2 acquisitions, including SpineMedica and Stability Biologics. Its website mimedx.com draws about 19 thousand monthly visits. MiMedx Group offers products and services including EPIFIX, EPICORD, AMNIOFIX, AMNIOCORD, and AXIOFILL. Its focus areas include Life Sciences, Regenerative Medicine, Biomaterials and Dressing. Its legal entity is MIMEDX Group, Inc. Its competitors include Theradaptive, RevBio and Aziyo Biologics; 3 of its 3 listed competitors have raised funding.
Company details
MiMedx Group was founded in 1985 and is headquartered in Marietta, United States. Operations center on regenerative medicine within the biomaterials sector, where products are processed from human amniotic membranes and collagen fibers for applications in wound care, surgery, sports medicine, and orthopedics. Key technologies encompass AmnioFix and EpiFix from donated placentas, CollaFix with cross-linked polymers, and OrthoFlo as an amniotic fluid allograft for tissue repair.
- Headquarters Marietta, United States
- Employees 837
- Stage Public
- SectorsHealthcare
- Website mimedx.com
- Social LinkedIn X Facebook
- Legal Name Mimedx Group, Inc
- Annual Revenue$418.63 M (USD)19.99as on Dec 31, 2025
- Net Profit$48.58 M (USD)14.52as on Dec 31, 2025
- EBITDA$78.77 M (USD)26.32as on Dec 31, 2025
- Latest Funding Round$100M (USD), Post-IPO
Jul 2020
- InvestorsHayfin
& 2 more
- Employee Count837
- Investments & AcquisitionsSpineMedica
& 1 more
Products & Services of MiMedx Group
MiMedx Group offers a comprehensive portfolio of products and services, including EPIFIX, EPICORD, AMNIOFIX, AMNIOCORD, and AXIOFILL.
Placental tissue product for promoting wound healing in patients.
Biologic for wound care to support tissue regeneration effectively.
Product aiding surgical healing with placental materials.
Biologic for surgical applications to enhance recovery processes.
Material for surgical use in tissue repair and support.
Funding Insights of MiMedx Group
- Total Rounds 6
- Last Round Post-IPO — $100M
- First Round $1.42M
(May 2009)
- Investors Count 3
All 6 funding rounds of MiMedx Group with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $100M | Post-IPO | – | – | |
| Jun 2019 | $75M | Debt – Conventional | – | – | |
| Dec 2013 | $34M | Post-IPO | – | – | – |
| Nov 2010 | $2.08M | Post-IPO | – | – | – |
| Nov 2009 | $675,000 | Post-IPO | – | – | – |
| May 2009 | $1.42M | Post-IPO | – | – | – |
3 investors in total: 3 institutional.
Investors in MiMedx Group
MiMedx Group has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Hayfin, EW Healthcare Partners and Blue Torch Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | ewhealthcare.com | New York, United States | ||
Private debt investments are directed across multiple sectors. | 2013 | hayfin.com | London, United Kingdom | |
Blue Torch Capital is engaged in private credit investment management. | 2017 | bluetorchcapital.com | New York, United States |
Investor details for MiMedx Group
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MiMedx Group
259 people are tracked at MiMedx Group (75 in leadership, 6 in board & advisors, 178 in team); the tracked headcount is 837.
| Name | Role | Group |
|---|---|---|
Brian Billips | Senior Regional Sales Director | Leadership |
Brock Boynton | Regional Director - Surgical West | Leadership |
Sarah Elliott | Regional Sales Director | Leadership |
Kevin Sewell | Regional Sales Director | Leadership |
Curt Routson | Director, Recovery Services | Leadership |
Curtis Campbell | Senior Director, Customer Service & Reimbursement Operations | Leadership |
Perri Stevens | Director, Regional Reimbursement | Leadership |
Christina Smith | Regional Sales Director | Leadership |
Justin Turner | National Director Of Field Reimbursement | Leadership |
Lora Whooley | Regional Sales Director | Leadership |
Wendall Warfield | Regional Sales Director | Leadership |
Brooke Shumaker | Regional Reimbursement Director | Leadership |
John-Paul Jendrek | Area Vice President Of Sales | Leadership |
Jennifer Solare | Regional Sales Director | Leadership |
Judy Slivinski | Regional Sales Director East | Leadership |
Alexander Draganov | Director, Process Innovation | Leadership |
Andrew Bresnock | Vice President | Leadership |
Allyn Forsyth | Director | Leadership |
Deidre Greve-Trout | Vice President Of Sales | Leadership |
Theresa Tardell | Director Human Resources | Leadership |
239 more people are available in the full profile.
Complete people profiles for MiMedx Group
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of MiMedx Group
MiMedx Group is a publicly listed company on the NASDAQ with ticker symbol MDXG in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Sep 2007
- Listed onNASDAQ: MDXG
- Listed entityMiMedx Group, Inc
- Exchange sectorHealth technology
- ISINUS6024961012
- Share price$4.69 (-2.9% on the day) · 2026-10-13
- Market capitalisation$683.6M
- Price to earnings119.0
- EPS (diluted, trailing year)$0.04
- Volume (last session)972,932
Financials of MiMedx Group
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $418.6M | $48.6M | $78.8M |
| 2024 | $348.9M | $42.4M | $62.4M |
| 2023 | $321.5M | $58.2M | $40.5M |
| 2022 | $267.8M | -$30.2M | -$10.7M |
| 2021 | $258.6M | -$10.3M | $1.2M |
Detailed financial statements for MiMedx Group
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MiMedx Group
MiMedx Group has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include SpineMedica and Stability Biologics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Bone and skin tissues are developed for medical grafting applications. | stabilitybio.com | Nashville, United States | 2010 | Jan 2016 | •••• | |
Spine alignment devices and artificial spinal implants | spinemedica.com | Marietta, United States | 2005 | Jul 2007 | •••• |
Complete acquisition details for MiMedx Group
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of MiMedx Group
6 dated milestones of MiMedx Group across 35 years, from founding to its latest funding, stage changes and deals.
- Founded MiMedx Group is founded.
- Acquisition Acquires SpineMedica.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.4M.
- Acquisition Acquires Stability Biologics.
- Funding Latest funding round, Post-IPO, of $100.0M.
Competitors of MiMedx Group
MiMedx Group has 3 listed competitors in our database, 3 of them funded. They include Theradaptive, RevBio and Aziyo Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| theradaptive.com | 2004 | Boston, United States | $32.2M | 21 | Therapeutic delivery platform is developed for orthopedic clinical indications. | |
| revbio.com | 2014 | Lowell, United States | $24.42M | Synthetic adhesives for bone and dental repair are developed. | ||
| aziyo.com | 2015 | Silver Spring, United States | $49.59M | 162 | Regenerative medicine products are developed for orthopedic and cardiovascular applications. |
Detailed competitors of MiMedx Group
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MiMedx Group
The website of MiMedx Group (mimedx.com) receives about 19.2K visits a month.
- Monthly visits19.2K
▲ 17.1% vs previous month
Websites whose visitors overlap most with MiMedx Group. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| invuity.com | 100% | View details | |||
ossatron.com | ossatron.com | 98% | – | ||
| aboutlawsuits.com | 96% | #636,003 | View details | ||
| woundsource.com | 96% | #389,677 | View details | ||
| promedica.org | 94% | 966.5K | #48,710 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 18 similar websites and full traffic analytics for MiMedx Group
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Orthopedics
3 companies that operate in the same segment as MiMedx Group (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mimedx Group
Complete news archive for MiMedx Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MiMedx Group
MiMedx Group was founded in 1985 and raised its 1st funding round 24 years after it was founded.
MiMedx Group is headquartered in Marietta, United States. It is registered at Marietta, Georgia, United States.
MiMedx Group has 837 employees.
Annual revenue of MiMedx Group is $418.63M as on Dec 31, 2025.
MiMedx Group was founded in 1985 and is headquartered in Marietta, United States. Operations center on regenerative medicine within the biomaterials sector, where products are processed from human amniotic membranes and collagen fibers for applications in wound care, surgery, sports medicine, and orthopedics. Key technologies encompass AmnioFix and EpiFix from donated placentas, CollaFix with cross-linked polymers, and OrthoFlo as an amniotic fluid allograft for tissue repair.
MiMedx Group's top competitors include Theradaptive, RevBio and Aziyo Biologics.
MiMedx Group offers EPIFIX, EPICORD, AMNIOFIX, AMNIOCORD, and AXIOFILL.
Yes, MiMedx Group is publicly traded on NASDAQ under the ticker symbol MDXG.
MiMedx Group has made 2 acquisitions, including SpineMedica, and Stability Biologics.
MiMedx Group has 3 investors. Key investors include Hayfin, EW Healthcare Partners, and Blue Torch Capital.
MiMedx Group operates through Mimedx Group, Inc..